Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOF/SMV/DCV/RBV in HCV GT4 patients with DAA failure
NCT04387539Phase 2Completed
- Sponsor
- Beni Suef University
- Start
- Mar 2017
- Primary completion
- Oct 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sofosbuvir, simeprevir, daclatasvir, ribavirin in Hepatitis C genotype 4 (HCV-4), sponsored by Beni Suef University. Started Mar 2017; status: completed.
02
Drugs
sofosbuvirsimeprevirdaclatasvirribavirin
03
Conditions
Hepatitis C genotype 4 (HCV-4)
Beyond the preview
Go deeper on NCT04387539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387539.